Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 4Active not recruiting 2Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2

Conditions

Lymphoma, Large B-Cell, Diffuse 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Recurrence 4Burkitt Lymphoma 3Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Neoplasm, Residual 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Biphenotypic, Acute 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Recurrence × tisagenlecleucel × Clear all
NCT03568461 2025-10-07

ELARA

Novartis

Phase 2 Completed
98 enrolled 9 charts 1 FDA
Lymphoid

Lymphoma, Follicular, Recurrence

NCT02445248 2024-04-18

JULIET

Novartis

Phase 2 Completed
115 enrolled 22 charts 1 FDA
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03123939 2021-07-21

Phase III B in Acute Lymphoblastic Leukemia

Novartis

Phase 3 Completed
69 enrolled 26 charts
LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02228096 2020-11-23

ENSIGN

Novartis

Phase 2 Completed
75 enrolled 41 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡